Last updated 2 months ago

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

375 patients around the world
Available in Spain, United States, Brazil
ArriVent BioPharma, Inc.
375Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy